Current and future trends of [18F]FDG PET/CT in pediatric Hodgkin lymphoma

[18F]FDG PET/CT plays a pivotal role in the contemporary management of malignant lymphoma, and is crucial for accurate staging, response assessment, and treatment planning in pediatric Hodgkin lymphoma (pHL). Treatment response evaluation in pHL and in particular interim [18F]FDG PET/CT done after few cycles of chemotherapy is critical for early prediction of outcome. It helps in identifying patients who would respond well and might safely omit radiotherapy, thereby reducing the risk of late adverse effects. Consequently, consensus international guidelines emphasize the standardized use of [18F]FDG PET/CT in pHL, thus facilitating comparison of clinical trial outcomes and optimizing individualized patient care worldwide. In the present review we aim to summarize essential aspects of [18F]FDG PET/CT in pHL, by providing new approaches and future developments.